[go: up one dir, main page]

AU2001281047A1 - Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin - Google Patents

Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin

Info

Publication number
AU2001281047A1
AU2001281047A1 AU2001281047A AU8104701A AU2001281047A1 AU 2001281047 A1 AU2001281047 A1 AU 2001281047A1 AU 2001281047 A AU2001281047 A AU 2001281047A AU 8104701 A AU8104701 A AU 8104701A AU 2001281047 A1 AU2001281047 A1 AU 2001281047A1
Authority
AU
Australia
Prior art keywords
subject
interferon
dosing regimen
ribavirin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281047A
Other languages
English (en)
Inventor
Peter Bowers
Loretta Itri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2001281047A1 publication Critical patent/AU2001281047A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001281047A 2000-08-02 2001-08-01 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin Abandoned AU2001281047A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22253800P 2000-08-02 2000-08-02
US60222538 2000-08-02
PCT/US2001/024426 WO2002010743A1 (en) 2000-08-02 2001-08-01 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin

Publications (1)

Publication Number Publication Date
AU2001281047A1 true AU2001281047A1 (en) 2002-02-13

Family

ID=22832621

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281047A Abandoned AU2001281047A1 (en) 2000-08-02 2001-08-01 Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin

Country Status (17)

Country Link
US (1) US20020052317A1 (pt)
EP (1) EP1325324A4 (pt)
JP (1) JP2004505114A (pt)
KR (1) KR20030043924A (pt)
CN (1) CN1466680A (pt)
AU (1) AU2001281047A1 (pt)
BR (1) BR0113179A (pt)
CA (1) CA2417550A1 (pt)
CZ (1) CZ2003311A3 (pt)
HK (1) HK1054432A1 (pt)
HU (1) HUP0303056A2 (pt)
MX (1) MXPA03001039A (pt)
PL (1) PL365664A1 (pt)
RU (1) RU2003102887A (pt)
WO (1) WO2002010743A1 (pt)
YU (1) YU7503A (pt)
ZA (1) ZA200301634B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6833351B2 (en) * 2001-05-21 2004-12-21 Douglas T. Dieterich Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
JP2004537569A (ja) * 2001-08-02 2004-12-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド エリスロポエチンおよび抗−腫瘍壊死因子アルファ組み合わせ療法
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
CA2525568C (en) * 2003-05-12 2017-07-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
BRPI0411172A (pt) * 2003-05-12 2006-07-18 Affymax Inc peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
EA010015B1 (ru) 2003-05-12 2008-06-30 Афимакс, Инк. Новый разделительный фрагмент (спейсер) для модифицированных полиэтиленгликолем соединений на основе пептидов
CA2548454C (en) * 2003-12-04 2013-12-31 Kyowa Hakko Kogyo Co., Ltd. Medicament comprising recombinant antibody against chemokine receptor ccr4
MX2007005777A (es) * 2004-11-11 2007-07-20 Affymax Inc Peptidos novedosos que se unen al receptor de eritropoietina.
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8563253B2 (en) * 2006-08-30 2013-10-22 Metanomics Gmbh Means and method for diagnosing hemolytic anemia
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572328B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para su uso en el tratamiento del vhc
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US10183968B2 (en) * 2011-10-31 2019-01-22 Merck Sharp & Dohme Corp. Methods of preparing lyophilized spherical-shaped pellets of biological materials
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU7473096A (en) * 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
TW586933B (en) * 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
EP1325324A1 (en) 2003-07-09
WO2002010743A1 (en) 2002-02-07
JP2004505114A (ja) 2004-02-19
US20020052317A1 (en) 2002-05-02
ZA200301634B (en) 2004-06-22
PL365664A1 (en) 2005-01-10
CA2417550A1 (en) 2002-02-07
EP1325324A4 (en) 2004-11-10
KR20030043924A (ko) 2003-06-02
BR0113179A (pt) 2004-06-22
YU7503A (sh) 2006-03-03
HUP0303056A2 (hu) 2003-12-29
HK1054432A1 (zh) 2003-11-28
CZ2003311A3 (cs) 2004-04-14
MXPA03001039A (es) 2004-09-10
CN1466680A (zh) 2004-01-07
RU2003102887A (ru) 2004-07-27

Similar Documents

Publication Publication Date Title
US20020052317A1 (en) Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
DE60018273T2 (de) Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie
US20070248572A1 (en) Method for treating diseases with omega interferon
WO2000067769A1 (en) Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
Morreale et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa
AU2002365436A1 (en) Method for treating diseases with omega interferon
JP2003525907A (ja) Ｈｉｖ免疫アジュバント治療
JP2784401B2 (ja) 慢性骨髄性白血病の治療方法
JP2000256211A (ja) Ｈｉｖ治療薬
US20090035273A1 (en) Combination treatment method with interferon-tau
Rodríguez et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon alpha-2b formulations administered intramuscularly in healthy male volunteers
TWI271196B (en) CML therapy
US20020182179A1 (en) HIV Therapy
HK1027286A (en) Hiv therapy
HK1068548B (en) Use of omega interferon in the manufacture of a medicament for treating hepatitis c
HK1068548A1 (zh) ω干擾素在製備用於治療丙型肝炎的藥物中的用途
HK1032348B (en) Chronic myeloid leukemia (cml) therapy

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application